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Abstract
Background: We previously reported the results of a phase 3 trial evaluating a prostate/rectal
hydrogel spacer during prostate intensity modulated radiation therapy, which resulted in decreased
rectal dose and toxicity and less decline in bowel quality of life (QOL). A secondary analysis was
performed to correlate penile bulb dose and sexual QOL.
Methods and materials: Sexual QOL was measured with the Expanded Prostate Cancer Index
Composite (EPIC) by mean scores, the proportion of patients with a minimal clinically important
difference (MID), and analyses of the different items composing the sexual domain.
Results: A total of 222 men enrolled with median follow-up of 37 months. Hydrogel reduced
penile bulb mean dose, maximum dose, and percentage of penile bulb receiving 10 to 30 Gy (all
P b .05) with mean dose indirectly correlated with erections sufficient for intercourse at 15 months
(P = .03). Baseline EPIC was low (53 [standard deviation ± 24]) with no difference between arms
(P N .1). A total of 41% (88/222) of men had adequate baseline sexual QOL (EPIC N60 (mean, 77
[± 8.3]). This subgroup at 3 years had better sexual function (P = .03) with a spacer with a smaller
difference in sexual bother (P = .1), which resulted in a higher EPIC summary on the spacer arm
(58 [±24.1] vs control 45 [± 24.4]) meeting threshold for MID without statistical significance (P =
.07). There were statistically nonsignificant differences favoring spacer for the proportion of men
with MID and 2× MID declines in sexual QOL with 53% vs 75% having an 11-point decline (P =
.064) and 41% vs 60% with a 22-point decline (P = .11). At 3 years, more men potent at baseline
and treated with spacer had “erections sufficient for intercourse" (control 37.5% vs spacer 66.7%,
P = .046) as well as statistically higher scores on 7 of 13 items in the sexual domain (all P b .05).
Conclusions: The use of a hydrogel spacer decreased dose to the penile bulb, which was associated with
improved erectile function compared with the control group based on patient-reported sexual QOL.
© 2017 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Intensity modulated radiation therapy (IMRT) is used
to treat men with prostate cancer with common bowel,
urinary, and sexual side effects. Sexual quality of life
(QOL) after prostate treatment is important, with 1 study
suggesting that 68% of men would risk a 10% greater
chance of dying in the first 5 years to achieve a 50%
improvement in the likelihood of maintaining good
erectile function.1
Following prostate radiation therapy (RT), 45% to 70%
of men retain potency at 2 years.2-4 Decreased blood flow
through the pudendal arteries posttreatment suggests that
RT-associated erectile dysfunction (ED) is predominantly
an arterial process.5,6 Higher RT dose to the penile bulb
(as a potential surrogate for other pelvic erectile/vascular
structures) has been demonstrated to increase the risk of
ED.7 Supporting this vascular role, phosphodiesterase
type 5 inhibitors can be effective in treating established ED
after RT8; however, prophylactic use during RT did not
clearly prevent new ED, with conflicting results from 2
randomized trials9,10; therefore, an approach to decrease
the risk of ED following RT is needed.
The SpaceOAR System (Augmenix, Inc., Bedford, MA)
is the only US Food and Drug Administration–approved
absorbable hydrogel that can be introduced between the
prostate and rectum to decrease rectal toxicity and minimize
changes in bowel QOL. Prior analyses of the pivotal phase 3
trial noted lower penile bulb radiation dose with spacer, but
there was no difference in average sexual QOL between
arms; however, because nearly 60% of men who had
moderate to severe sexual dysfunction at baseline, it is
possible that an impact of the spacer on sexual function was
masked. This post hoc analysis identified the subgroup of
men with adequate baseline sexual QOL (41% of respon-
dents) and found a correlation between reduced RT dose to
penile bulb and better sexual QOL as well as quality of
erections when comparing the spacer arm with control.
Methods and materials
Patient population and treatment
As previously reported, following institutional review
board approval, men with National Comprehensive Cancer
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Network low- or intermediate-risk prostate cancer were
randomized 2:1 (spacer:control) with all receiving fiducial
markers and IMRT (clinicaltrials.org; NCT01538628).
Patients were blinded to treatment allocation.11,12
The postfiducial planning computed tomography and
magnetic resonance imaging scans were fused, and
structures were contoured on fused images. Clinical target
volume was the prostate ± seminal vesicles. Planning
target volume margins were 5 to 10 mm. Treatment was
79.2 Gy in daily fractions of 1.8 Gy. Radiation plans were
evaluated by a core laboratory for protocol compliance
(H.G., W.B., J.M.). The penile bulb dose was collected,
but there were no planning goals for this structure.
Data collection and follow-up
For QOL, men were followed at enrollment, 3, 6, 12,
15, and 36 months. The primary endpoint was reported at
15 months.11 Extended follow-up beyond 15 months was
performed at those institutions electing to participate in
this extended study.12
Statistical analysis
The EPIC sexual domain is provided in Appendix E1
(available as supplementary material online only at www.
practicalradonc.org).13 At baseline, 96% (212/222) of men
answered all sexual QOL questions and were the study
group. Based on a previously established threshold, men
were dichotomized as having adequate sexual function
(EPIC N60, n = 88, 41%) or moderate/poor sexual function
(EPIC ≤60, n = 125, 59%).14 Mean changes in EPIC
sexual summary scores from baseline were evaluated in
linear mixed models with fixed effects of randomized
treatment, questionnaire time point, baseline domain score,
and the interaction of randomized treatment and question-
naire time point and repeated measures within patient
accounted for with an autoregressive correlation structure.
Pairwise testing was done within the modeling framework.
Minimal clinically important differences (MIDs) were
evaluated based on a previously published threshold of 11
points (range, 10-12) and twice that threshold (22 points).15
The single question “How would you describe the usual
QUALITY of your erections during the last 4 weeks?”was
analyzed across the full scale or dichotomized with the
favorable group reporting “Firm enough for intercourse”,4
whereas the unfavorable group reported all other responses
(“None at all” (1), “Not firm enough for any sexual
activity”,2 or “Firm enough for masturbation only”.3,16
Each of the other items in the EPIC sexual domain were
analyzed in a similar fashion assessing the proportion with
“moderate” to “severe” dysfunction or bother as indicated.
The response was compared with baseline at each time
point and then dichotomized into “worse” versus “the
same or better.” Binomial proportions and 95% confidence
intervals (CIs) are reported by penile bulb dose constraint
(percentage of penile bulb receiving doses ≥50 Gy [V50]
and mean) with associated χ2 test and odds ratios (ORs)
between meeting the constraint or not.
Analysis was performed in SAS 9.4 (SAS Institute,
Cary, NC). For all analyses P values b.05 were considered
statistically significant. No corrections for multicompar-
isons were performed.
Results
Between January 2012 and April 2013, 222 eligible men
enrolled at 20 US institutions and were randomized 2:1
(spacer:control). The primary endpoint was reported at 15
months11; extended follow-up continued through April 2016,
when 63%of both control (n = 46) and spacer (n = 94) patients
were evaluable.12 There was no difference in median
follow-up between arms (control: median, 37.0 months
[range, 26-46] vs spacer 37.1 [32-47], P N .5).
Demographics
There were no differences between arms in age
(control, 67.7 years; spacer, 66.4; P = .2), race (control,
84% white; spacer, 85%; P = .8), or body mass index
(control, 29 kg/m2; spacer, 29; P = .6). Baseline sexual
QOL by EPIC was poor (mean 53 [±24 standard
deviation]) with 59% having moderate/severe sexual dys-
function (defined as an EPIC score of≤60)with no difference
between arms (control, 58%; spacer, 61%; P N .1). Only 38%
(80/213) of respondents had both adequate baseline sexual
QOL and “erections firm enough for intercourse,” which did
not differ by arm (spacer, 39% [n = 56]; control, 34% [n = 24];
P =.22). Androgen deprivation was not allowed and no
patients experienced biochemical failure or salvage therapy.
Dosimetry and sexual function
As previously reported, spacer use was associated with
lower penile bulb dose for mean dose (21 vs 11 Gy),
maximum dose (46 vs 36 Gy), and V10 to V30 (Fig 1A, all
P b .05).To address the potential clinical significance of
these differences, suggested cut-points for penile bulb dose
were evaluated (Fig 1B).17 Mean values were lower than
suggested for all constraints for both arms; however,
across all dose constraints, those on the spacer arm were
more likely to achieve these constraints: 71% to 79% for
spacer compared with 53% to 75% for control.
At enrollment, 38% (80/213) of men had erections firm
enough for intercourse, which were maintained in 71%
(55/77) at 3 months, 86% (69/80) at 6 months, 70% (56/
80) at 12 months, 72% (57/79) at 15 months, and 57% (28/
49) at 36 months. Given low baseline potency and the 63%
response rate at 36 months, we focused dose-modeling on
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the 15-month time-point, where response rates were
N96%. Mean penile bulb dose for all men was 14.3 Gy,
which was broken into tertiles for analysis (Fig 2A). There
was an inverse correlation between penile bulb dose and
erections sufficient for intercourse (P= .03). Similarly, when
looking at the predetermined dose constraints (Fig 2B) at 15
months, those achieving the specified dose constraints were
more likely to have erections sufficient for intercourse than
those not achieving the constraints. Those who did not meet
the dosimetric goals had 29% to 35% potency as compared
with 44% to 47% in those who did.
The question on “quality of erections”was also evaluated
as a function of V50 (b20% vs≥20%) and mean dose (b23
vs ≥23 Gy) over time (Fig 2C, Table E1). Baseline erectile
A
B
Figure 1 (A) Penile bulb dose in 5-Gy increments (5-80 Gy). Dose bins indicated with an asterisk (*) were statistically different (P b
.05). (B) The proportion of patients by treatment arm achieving the dose constraints recommended based upon the Conventional or
Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer trial (goals are indicated in parentheses).
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function (P b .001) and time since RT (P b .001) both
correlated with erectile function, whereas higher penile bulb
dose correlated with a greater likelihood of a decline in
erectile function on the 4-step Likert scale. The curves began
separating as early as 6 months posttreatment but were only
statistically different for V50 at 15 months (P = .007; OR, 2.4
[95% CI, 1.3-4.7]) and for mean dose at 12 months (P = .01;
OR, 2.2 [95% CI, 1.2-4.2]) and 15 months (P = .01; OR, 2.3
[95% CI, 1.2-4.3]).
EPIC sexual summary score as a function of
treatment arm
As previously reported, there was no significant
difference between EPIC summary score based upon
randomization (P = .6, Figure E1).11,12 Those with minimal
to no sexual dysfunction at baseline (EPIC N60) had better
sexual function at 36 months with the use of spacer (55.4;
standard error of the mean [SEM], 3.9) compared with
control (41.3 [SEM, 5.1],P = .033) with a smaller difference
in sexual bother (57.7 [SEM, 4.1] vs 44.5 [SEM, 5.4], P =
.10), which resulted in a borderline difference in overall
sexual summary score (P = .07, Fig 3A). For those
with better baseline QOL, the difference in EPIC
summary score favoring spacer at 15 (P = .069) and
36 months (P = .058) of 10 and 13 points, respectively,
crossed the threshold for an MID of 10 to 12 points. 15
There was no difference in function, bother, or sexual
summary score in those with poor baseline QOL (EPIC
≤60, P N .5, Fig 3B).
For men with good baseline QOL (EPIC N60), we
assessed the likelihood of having 11- or 22-point declines
in QOL summary (where 11 points is a threshold
established as an MID and 22 points is twice that
threshold). A statistically nonsignificant difference was
noted in the proportion having 1× MID declines on the
control (75%) compared with the spacer arm (54%) at 36
months (P = .06, Fig 4A). There was a similar relationship
for the 2× MID threshold, suggesting clinical significance
even though statistical significance was not reached,
with 60% of control men having a 22-point decline at
36 months compared with 41% of spacer men (P = .11,
Fig 4B).
ED as a function of treatment arm
At baseline, 96% of men completed the sexual portion
of the QOL survey; 41% had adequate sexual QOL (EPIC
N60), 89% of this subset had erections sufficient for
intercourse, and of these, response rate to the extended
follow-up study was 63%. To measure erections sufficient
for intercourse at baseline and 36 months, this yielded a
usable sample of 22% (0.96 × 0.41 × 0.89 × 0.63 = 0.22) of
those who enrolled (n = 49 [spacer, n = 33; control, n = 16]).
In this group of men, the use of a spacer resulted in a greater
likelihood of having erections firm enough for intercourse
in the preceding 4 weeks (P = .049), which was apparent
from 6 months onward and reached a difference of 67%





Figure 2 (A) Erections firm enough for intercourse at 15
months as a function of penile bulb dose broken down by tertiles.
(B) Erectile function assessed by the dose constraints recom-
mended based upon the Conventional or Hypofractionated High
Dose Intensity Modulated Radiotherapy for Prostate Cancer trial.
(C) Erectile function over time by V50 and mean dose. *P b .05.
Dmax, maximum dose; RT, radiation therapy; V50, percentage
of penile bulb receiving doses ≥50 Gy.
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Individual EPIC items
To gain a robust understanding of differences between
arms, the responses to the individual EPIC items were
analyzed when stratified by those with better (Table 1) or
worse (Table E2) sexual QOL at baseline. All responses
were included (regardless of whether men answered at
each time point) and were dichotomized as noted. For
those with worse baseline sexual QOL upon enrollment,
there were no differences with a spacer for any items.
In the men with better QOL at baseline, although there
were no differences between control or spacer at
randomization, at 3 years there were statistically signifi-
cant differences for 6 of 9 functional items and 1 of 4
bother all favoring spacer (Table 1, Fig 5B). For example,
no men reported erection ability as “very poor” or “poor”
at baseline, but at 3 years this was 47% in the control arm
compared with 19% in the spacer arm (P b .05). Similarly,
“moderate” to “severe” sexual bother increased by 41% in
the control arm versus 18% in the spacer arm (P b .05).
Discussion
The results for changes in sexual QOL reported here
after IMRT are similar to those previously published.18
Despite differences in penile bulb dose, we did not detect
an overall difference in QOL with the prostate/rectal
spacer.12 Nevertheless, given the many men with poor
baseline function, we hypothesized a substantial “floor
effect” by which QOL would not worsen due to incident
ED. This was clearly demonstrated when limited to the
59% of men with poorer baseline sexual QOL because
there was no discernible difference between arms at 3
years and only a 4-point decline (on a 0-100 scale) in
average sexual summary score. When limited to the 41%
of men with better baseline EPIC scores, however, there
was a 23-point decline with an apparent meaningful
13-point difference between arms (P = .07) that manifested
as greater differences in sexual function (P = .03) than
sexual bother (P = .1). These results suggest that in
A
B
Figure 3 Expanded Prostate Cancer Index Composite (EPIC)
sexual summary score over time (and standard deviation) as a
function of treatment arm for those with better sexual quality of
life (EPIC N60) at baseline (A) or for those with moderate-severe
sexual dysfunction (EPIC ≤60) at baseline (B).
A
B
Figure 4 For men with better baseline sexual function (EPIC
N60), the percentage of patients over time by treatment arm
having a decline in sexual function meeting threshold for MID
(11 points) (A) or 2× MID (22 points) (B). ED, erectile
dysfunction; QOL, quality of life; MID, minimal clinically
important difference. See Fig 3 for other abbreviations.
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appropriately selected men the spacer may lead to an
improvement in sexual QOL after IMRT.
Based upon previous analyses, those with an EPIC
summary score N75 are defined as having no sexual
dysfunction, whereas those patients with scores of 61 to 75
have mild sexual dysfunction and those with lower scores
have moderate to severe sexual dysfunction.14 We used a
subset analysis based upon this previously established
stratification (≤60 vs N60). The MID for this instrument
has been documented as 10 to 12 points.16 In those
patients with better baseline summary, we found a
10-point difference between randomized arms at 15
months and a 13-point difference at 36 months, although
neither was statistically significant. In addition, consistent
with other analyses, we also assessed potency using the
single question on erections firm enough for intercourse
where there were more effective erections at 3 years for
spacer (67%) compared with control (38%, P = .049)
groups.16 As such, the number needed to treat to preserve
erectile function in 1 man at 3 years was 3.4. In addition,
for all 13 questions in the sexual domain, there were
numeric differences favoring spacer for 12 of 13 questions,
which were statistically different for 7 (6 in the functional
domain and 1 in the bother domain).
We observed that 70% of men maintained erectile
function at 1 year and 57% at 3 years in both arms of the
study. Recently a population-based analysis using EPIC
found erections sufficient for intercourse of 53% at 3 years
following external beam RT.18 Others have reported rates
of potency preservation between 41% and 70% at 2
years.3,4,19-21 However, differences in radiation technique,
dose, and the QOL instruments make these comparisons
difficult. Recently, the use of magnetic resonance imaging
scans planned “vessel sparing” IMRT (most delivered
with combined IMRT and brachytherapy) reported
erections suitable for intercourse of 87% at 2 years for
men potent at baseline, which was substantially better
than predicted.22
Several studies have looked at the association between
penile bulb radiation dose and ED following external beam
A
B
Figure 5 (A) Erections firm enough for intercourse as a function of treatment arm for men with EPIC N60, who had erections sufficient
for intercourse at baseline, and responded at baseline and 3 years. (B) The difference in the percentage of men with good baseline function
reporting “moderate” to “severe” problems for each of the EPIC sexual domain items between baseline and 3 years as a function of
treatment arm. *P b .05. Abbreviation as in Fig 3.
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RT.23 In the Radiation Therapy Oncology Group 9406
trial, there was higher ED for those with penile bulb dose
greater than the median (52.5 Gy).4 Others noted
correlations between ED and doses to the penile bulb at
30, 45, 60, and 75 Gy.24 Analysis of the Conventional or
Hypofractionated High Dose Intensity Modulated Radio-
therapy for Prostate Cancer (CHHiP) trial from Great
Britain established a broad range of dosimetric goals, and
we identified a higher likelihood of achieving these goals
with the use of the prostate/rectal spacer as well as a
correlation between meeting these goals and maintaining
erectile function. Not all studies support the association
between penile bulb dose and ED; however, a
meta-analysis of 8 such studies scored the reliability of
reports and found a higher quality of studies in those
supporting the association between penile bulb dose and
ED than those unable to find such an association.25
Despite the associations noted between penile bulb
dosimetry and the use of the prostate rectal spacer, it is
unclear why the use of a spacer resulted in a reduction in
penile bulb dose. One possibility is that, with the use of
inverse optimization, the treatment planning algorithms
will favor solutions that attempt to spare the rectum with
less priority placed on structures with lower priority such
as the penile bulb. If the planning system has difficulty
achieving rectal goals, it is unlikely that the planning
process will routinely lead to favorable penile bulb doses;
however, if the use of a rectal/prostate spacer substantially
decreases the dose to the rectum, this may increase the
ability of the optimization algorithm to address secondary
planning goals such as the penile bulb. The average doses
achieved for the penile bulb were favorable compared with
many previous studies (mean dose: control, 21; spacer, 11
Gy). Nevertheless, a dose-dependent relationship between
dose and erectile function was observed even with these
lower doses, which was 51% for b8 Gy, 40% for 8 to 24
Gy, and 34% for N24 Gy (P = .03). This is consistent with
a recent report from the UK CHHiP trial that advocated a
mean penile bulb goal of b20 Gy and is thus suggestive
that it may be appropriate to target even lower penile bulb
doses than have been previously recommended.17,26
Given that a penile bulb dose of 21 Gy is already
considered acceptable by most standards, it is likely that
no further effort was placed to reduce doses. We postulate
that if there was more emphasis to reduce doses, lower
doses could have been obtained in the control arm, which
could have partially mitigated the effect seen with a spacer.
There are a number of limitations to such post hoc sub
set analysis. The small sample size of patients with
adequate sexual function at baseline limited the ability to
detect differences. Within this small defined subset,
differences in overall EPIC summary score (average and
the proportion with MID) were suggestive of a difference
but did not achieve statistical significance (P = .06-.07).
Furthermore, analysis of the single question on erectile
function did suggest a difference in quality of erections
firm enough for intercourse over time (P = .049). For all
questions in the sexual domain, statistical differences were
identified in 7 of 13 items, each favoring the spacer arm.
Nevertheless, there are also several strengths in the current
analysis, including that the results were from a blinded
phase 3 trial in which sexual QOL was prospectively
Table 1 Individual sexual items in those with better baseline sexual function
Control (n = 28) Spacer (n = 60)




Desire (very poor/poor) 3.6 15.4 14.3 21.4 19.2 30.0 3.3 22.0 13.3 15.0 15.0 14.7
Erection ability
(very poor/poor)
0.0 12.0 17.9 20.0 28.0 47.4a 0.0 12.1 8.5 20.3 17.0 18.8a
Orgasm ability
(very poor/poor)
0.0 24.0 14.3 20.0 24.0 42.1a 0.0 13.8 6.8 11.9 11.9 12.9a
Erection quality (bintercourse) 14.3 30.8 25.0 39.3 42.3 65.0a 6.7 30.5 15.0 30.0 26.7 35.3a
Erection Frequency
(bhalf desired)
3.6 23.1 14.3 17.9 23.1 50.0a 1.7 15.3 8.5 11.7 15.0 17.7a
Awaken erection (b1/wk ) 39.3 53.9 50.0a 60.7a 72.0a 75.0a 25.0 37.3 28.3a 31.7a 33.3 41.2a
Sex activity (b1/wk) 28.6 46.2 35.7 53.6 42.3 60.0 30.0 39.0 36.7 45.0 38.3 47.1
Intercourse (b1/wk) 39.3 50.0 57.1 64.3 57.7 75.0 38.3 49.2 41.7 56.7 51.7 61.8
Overall function
(very poor/poor)




Desire 0.0 11.5 7.1 18.5 32.0a 20.0 3.3 15.3 15.3 18.3 13.3a 26.5
Erection ability 0.0 16.0 17.9 25.9 33.3 50.0 0.0 15.3 10.2 21.7 16.7 35.3
Orgasm ability 3.6 12.0 17.9 26.9 20.8 40.0 0.0 17.0 8.5 18.6 10.0 20.6
Overall 3.6 7.7 10.7 21.4 19.2 45.0a 0.0 17.0 10.2 15.0 15.0 17.7a
Responses to individual items on sexual domain dichotomized based upon sexual function as indicated and for sexual bother dichotomized based upon the
percentage of patients reporting “moderate or big” bother for each item. aItems statistically different between the control and spacer groups (χ2 P b .05).
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collected as part of planned analyses; in addition, there
were no differences between arms in baseline QOL, age,
race, body mass index, treatment, follow-up, or response.
Although these conclusions are based on an unplanned
analysis, the cut-points both for subset analysis and
determination of MID were selected based on previously
established thresholds. In addition, the analysis of penile
bulb dosewas preplanned, andwe did see dosimetric differences
that were statistically significant and fit within the context of
multiple previous studies associating penile bulb dosimetry and
ED. It is also worth noting that no previous prospective
randomized trials of other radiation treatmentmodalities (such as
IMRT, image guidance, proton therapy, or stereotactic therapy)
have identified such an improvement in ED and sexual QOL.
These reported results, although provocative, have a number of
limitations and must be viewed as hypothesis generating with
further studies needed to validate the observations.
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